Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CordSTEM-ST (CBT210-POI) is an allogeneic cell therapy developed by CHABiotech, consisting of human umbilical cord-derived mesenchymal stem cells (UC-MSCs). It is specifically designed for the treatment of premature ovarian insufficiency (POI), a condition where ovaries stop functioning normally before the age of 40, often leading to infertility. The therapy works by leveraging the regenerative and paracrine properties of MSCs to restore ovarian function, potentially through the secretion of growth factors that promote follicular development and reduce apoptosis in ovarian cells. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and preliminary efficacy in restoring hormonal balance and ovarian activity in women with a history of ovarian failure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CordSTEM-ST.